Profile: Aeterna Zentaris Inc (AEZS.O)
20 Jan 2017
Aeterna Zentaris Inc., incorporated on October 12, 1990, is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Zoptrex represents a targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier, zoptarelin, and a chemotherapy agent, doxorubicin, resulting in a cytotoxic conjugate. Zoptrex is an intravenous drug that is considered to direct the chemotherapy agent specifically to LHRH-receptor expressing tumors. The Company is conducting a Phase III clinical study of Zoptrex in women with recurrent or metastatic endometrial cancer who have progressed and who have received a chemotherapeutic regimen with platinum and taxane (either as adjuvant or first-line treatment). The clinical study is known as the ZoptEC study (zoptarelin doxorubicin in endometrial cancer). ZoptEC is a fully-recruited (over 500 patients), open-label, randomized-controlled study, comparing the safety of Zoptrex to doxorubicin alone. The Company is attempting to commercialize Zoptrex as a treatment for endometrial cancer.
Macrilen is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and that has uses in both endocrinology and oncology indications. Macrilen has been granted orphan-drug designation by the Food and Drug Administration (FDA) for use in evaluating growth hormone deficiency (GHD).
Aeterna Zentaris Inc
1 Ville-Marie Pl Suite 2500
MONTREAL QC H3B 1R1
Company Web Links
- BRIEF-Aeterna zentaris Q3 loss per share $0.61
- BRIEF-Aeterna Zentaris says announces $7.6 mln registered direct offering
- BRIEF-Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen
- BRIEF-Aeterna and Specialised Therapeutics Asia sign exclusive license agreement
- BRIEF-AEterna Zentaris announces expiration of remaining Series B warrants